Skip navigation
Skip navigation
You are using an outdated browser. Please upgrade your browser.

Life Sciences Supercomputing Guru Drives Platform’s Solutions for
Computational Biology, Bioinformatics, Functional Genomics and Drug Discovery

Platform Computing, the global leader in distributed computing software, today announced the appointment of Yury Rozenman as Life Sciences business development manager. With more than 13 years of scientific and bioinformatics experience, Rozenman was mostly recently Senior Vice President of Supercomputing and Bioinformatics at Juno Online Services, where he was responsible for distributed computing infrastructure development, business development and sales strategy for the Virtual Supercomputing Project.

In his new position, Rozenman will direct Platform’s Life Sciences strategy for Platform’s growing Life Sciences division and communicate the strengths and capabilities of Platform’s solutions to research institutes and pharmaceutical companies around the world, with clients such as the Sanger Centre, EBI and Celera Genomics. He will also lead the formation of new strategic alliances with original equipment manufacturers (OEMs), independent software vendors (ISVs) and system and enhance Platform’s current relationships with partners such as LION Bioscience, IBM, SGI and Compaq.

Prior to joining Juno Online Services, Rozenman was a Senior Software Consultant and Strategist at Applied Biosystems Inc., a division of Applera Corporation. Rozenman also worked as a research investigator at G. D. Searle Pharmaceutical Company in Chicago, where he was responsible for the development and implementation of new methods of analysis for new pharmaceutical entities. He is a graduate of the University of Illinois at Chicago.

Life Sciences organizations around the globe are incorporating Platform’s distributed computing solutions into the discovery process to maximize the productivity and potential of their existing technology investments. Platform seamlessly integrates with and distributes application workload, allowing scientists to exploit and analyze diverse types and sources of biological data in a shorter period of time; deliver more accurate results to reduce failure rates; and, enable better decision-making earlier in the discovery process.

Platform solutions currently distribute computing jobs to servers and workstations in more than half of the Fortune 500 pharmaceutical and chemical companies. Platform has helped the Sanger Center, a world-leading genome research center based in the UK, to crack the DNA code of Chromosome 22, paving the way for huge advances in medical diagnosis and treatment. Platform also played an integral role in helping Celera Genomics, an integrated source of genomic and related medical information, to map the human genome more than two years ahead of schedule.

About Platform:
Platform is the world’s leading distributed computing software provider, with desktop to Grid solutions that allow organisations to dramatically improve time to market and quality of results, while maximising their I.T. investment. Platform has strategic relationships with industry leaders including Compaq, HP, IBM, SGI, Sun, LION Bioscience, Cadence and SAS Institute and its open, scalable software solutions are the choice of more than 1,500 result-driven organisations around the world. Platform is an independent company with 400 employees in 14 offices in North America, Europe and Asia. For more information visit

For more information, please contact:
Richard Bennett or Tamsin Keynton,
MCC International,
Tel: +44 (0)1962 888100,
Fax: +44 (0)1962 888125,,

This press release was distributed by ResponseSource Press Release Wire on behalf of MCC International Ltd in the following categories: Consumer Technology, Personal Finance, Business & Finance, Computing & Telecoms, for more information visit